High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia.
We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for refractory gestational trophoblastic neoplasia (GTN) in the largest series so far reported. In all, 11 patients have been treated at three Trophoblast Centres between 1993 and 2004. The conditioning regimens comprised either Carbop-EC-T (carboplatin, etoposide, cyclophosphamide, paclitaxel and prednisolone) or CEM (carboplatin, etoposide and melphalan) or ICE (ifosfamide, carboplatin, etoposide). Two patients had complete human chorionic gonadotrophin responses, one for 4 and the other for 12 months. Three patients had partial tumour marker responses for 1-2 months. High-dose chemotherapy and HSCS for GTN is still unproven. Further studies are needed, perhaps in high-risk patients who fail their first salvage treatment.
El-Helw
L M
LM
YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham road, Sheffield S10 2SJ, UK.
Seckl
M J
MJ
Haynes
R
R
Evans
L S
LS
Lorigan
P C
PC
Long
J
J
Kanfer
E J
EJ
Newlands
E S
ES
Hancock
B W
BW
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002822:Choriocarcinoma / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D036102:Peripheral Blood Stem Cell Transplantation; D011247:Pregnancy; D016879:Salvage Therapy; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000628:therapy*